drugset / Trial / NCT04307147
NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, randomized, open-lable phase III clinical trial evaluating the effectiveness and safety of vinorelbine plus capecitabine as adjuvant treatment for non-pCR Luminal B breast cancer patients after standard neoadjuvant chemotherapy.
Timeline
- Start
- 2018-07-03
- Primary completion
- 2021-03-01
- Completion
- 2021-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |